TRIM9 switches the morphological phenotype of melanoma cells

This study demonstrates that the E3 ubiquitin ligase TRIM9 regulates melanoma cell proliferation and morphology by interacting with VASP to modulate actin organization and adhesion, thereby suppressing mesenchymal motility and influencing tumor growth and metastasis.

The Gist

The Big Picture: The "Shape-Shifting" Cancer

Imagine melanoma (a dangerous type of skin cancer) not as a static lump, but as a master of disguise. It's a "chameleon" cancer. Sometimes it stays put and multiplies rapidly (like a factory churning out products). Other times, it breaks loose, changes its shape, and scatters to other parts of the body (like a spy sneaking out to cause trouble elsewhere).

This study discovered a specific protein called TRIM9 that acts like a remote control for this shape-shifting. When TRIM9 is present, the cancer cells behave one way. When TRIM9 is missing, they behave completely differently.

The Discovery: What TRIM9 Actually Does

The researchers found that TRIM9 is a "traffic cop" inside the cell, specifically managing the cell's internal skeleton (made of actin fibers) and its sticky feet (adhesions).

1. The "Bleb" vs. The "Spread"

• With TRIM9 (The Round Ball): The cancer cells tend to stay round and bouncy, like a water balloon. They detach from the surface and "bleb" (bubble up). This is a fast, rolling way to move, often used when the cell is in a hurry or trying to survive in tight spaces.
• Without TRIM9 (The Spaghetti): When the researchers removed TRIM9, the cells stopped being round balls. Instead, they flattened out, spread their legs wide, and grabbed onto the surface tightly. They looked more like a spider or a piece of tape that had been pressed down.

2. The Internal Engine: VASP
Inside the cell, there is a protein called VASP. Think of VASP as the construction crew that builds the cell's skeleton.

• Normally: TRIM9 keeps VASP in check. It puts a "speed bump" on VASP, slowing it down and keeping it in specific spots.
• Without TRIM9: The speed bump is gone. VASP goes wild. It rushes to the cell's "sticky feet" (focal adhesions) and builds massive, strong bundles of skeleton fibers. This makes the cell super sticky and strong, but it changes how the cell moves.

The Consequences: Speed vs. Strength

The study found that this switch in shape changes how the cancer behaves in two very different ways:

In the Lab (The "Test Tube" World):

• Without TRIM9: The cells became stronger and stickier. They could pull harder on their environment (like a weightlifter) and they moved faster in a straight line. They were also better at chewing through barriers (degrading the matrix) to invade new areas.
• With TRIM9: The cells were rounder, moved in a more chaotic "rolling" fashion, and multiplied (reproduced) much faster.

In the Mouse (The "Real World"):
This is where it gets tricky. You might think, "If the cells without TRIM9 are stronger and faster, they should cause more cancer." But nature is complex.

• With TRIM9: The tumors grew huge very quickly because the cells were reproducing like crazy. However, they didn't spread as far.
• Without TRIM9: The tumors grew slower (because the cells weren't reproducing as fast), but they were sneakier. They managed to spread to the lungs and liver in different patterns.

The Analogy:
Think of TRIM9 as a manager at a construction site.

• When the Manager (TRIM9) is there: The workers (cells) are busy building a massive skyscraper (the tumor). They are focused on growth and reproduction. They don't leave the site much.
• When the Manager is fired (TRIM9 deleted): The workers stop building the skyscraper as fast. Instead, they pack up their tools, become very strong and agile, and start running off to build smaller, scattered shacks in different cities (metastasis).

Why This Matters for Patients

The researchers looked at data from real human patients and found a scary trend:

• Patients with high levels of TRIM9 in their tumors tended to have worse survival rates.
• These patients also responded poorly to immunotherapy (the "checkpoint inhibitors" that help the immune system fight cancer).

The Takeaway:
TRIM9 seems to be the switch that turns a slow-growing, sticky cell into a fast-reproducing, aggressive tumor. By understanding how TRIM9 controls the cell's "remote control," scientists might be able to figure out how to stop the cancer from switching into its most dangerous modes or help the immune system recognize it better.

Summary in One Sentence

TRIM9 is a protein that tells melanoma cells to stop being sticky and slow, and instead become round, fast-reproducing factories that grow huge tumors and are harder for the immune system to stop.

Technical Summary

1. Problem Statement

Melanoma is a highly plastic cancer characterized by the ability of cells to switch between distinct phenotypic states (e.g., proliferative melanocytic, invasive neural-crest-like, and mesenchymal states). These transitions are driven by unique gene expression profiles and are central to tumor aggressiveness, drug resistance, and metastasis.

• The Gap: While TRIM9 (a brain-enriched E3 ubiquitin ligase) was identified as a top differentially expressed gene capable of classifying melanoma cell lines, its specific role in regulating melanoma phenotype switching and disease progression remained unknown.
• The Question: How does TRIM9 expression influence melanoma cell morphology, proliferation, motility, and metastasis, and what are the underlying molecular mechanisms?

2. Methodology

The study employed a multi-faceted approach combining in vitro cell biology, in vivo mouse models, and molecular biochemistry:

• Cell Models: Two metastatic human melanoma cell lines (1205Lu and WM266-4) were used.
  • Genetic Manipulation: CRISPR-Cas9 was utilized to generate stable TRIM9 knockout (KO) cell lines (TRIM9-/-) to delete both long and short isoforms.
  • Rescue/Interaction Studies: Transient expression of Halo-tagged TRIM9 (including a ligase-dead mutant, TRIM9ΔRING) and GFP-tagged VASP (wild-type and a ubiquitination-deficient mutant, VASPKR) were used for co-immunoprecipitation and functional assays.
• In Vivo Model: A genetically engineered mouse (GEM) model (PBT-Trim9) was used. This model harbors Pten deletion and constitutively active BrafV600E (common melanoma drivers) and allows for the inducible deletion of Trim9 specifically in melanocytes via Tyr:CreER upon tamoxifen application. Tumors were induced on the ear to monitor primary growth and metastasis.
• Phenotypic Assays:
  • Morphology: Cell spreading, circularity, and blebbing were quantified on glass, soft (2 kPa), and stiff (75 kPa) polyacrylamide hydrogels.
  • Cytoskeleton & Adhesion: Immunofluorescence for F-actin (phalloidin), VASP, and paxillin. Quantification of filopodia/lamellipodia dimensions, stress fiber bundling, and focal adhesion (FA) number/shape.
  • Dynamics: Fluorescence Recovery After Photobleaching (FRAP) was used to measure turnover rates of VASP, zyxin, and paxillin at focal adhesions.
  • Motility & Invasion: Random migration assays, collagen gel contraction assays (contractility), and Transwell invasion assays.
  • Secretion: Gelatin zymography and Western blotting for Matrix Metalloproteinases (MMPs) and Netrin-1.
• Molecular Analysis: Co-immunoprecipitation (Co-IP), Western blotting for phosphorylation (p-VASP Ser157), and ubiquitination status.

3. Key Contributions

• Discovery of TRIM9 as a Phenotype Switch Regulator: The paper establishes TRIM9 as a critical regulator that drives melanoma cells toward a bleb-based, proliferative phenotype while suppressing a mesenchymal, adhesive, and invasive phenotype.
• Mechanistic Link to VASP: The study elucidates a novel mechanism where TRIM9 physically interacts with the actin polymerase VASP, regulating its phosphorylation (Ser157) and ubiquitination. This interaction dictates VASP localization between the leading edge (lamellipodia/filopodia) and focal adhesions.
• Context-Dependent Function: The paper highlights that TRIM9's role in melanoma is distinct from its role in neurons (where it promotes filopodia). In melanoma, TRIM9 loss leads to increased adhesion and contractility, contrasting with its known tumor-suppressive or tumor-promoting roles in other cancer types.

4. Key Results

A. TRIM9 Regulates Morphology and Blebbing

• Phenotype: TRIM9-/- melanoma cells exhibited a spread, polarized, mesenchymal morphology with increased cell area and reduced circularity. Conversely, TRIM9+/+ cells displayed a circular, bleb-like morphology, particularly on soft substrates.
• Blebbing: High TRIM9 expression promoted blebbing (a mode of migration associated with low adhesion and high contractility). Loss of TRIM9 significantly reduced the time cells spent in a bleb-like state.

B. Cytoskeletal Reorganization and Focal Adhesions

• Actin Architecture: TRIM9-/- cells showed reduced filopodial length and density but increased filopodial width. Lamellipodia became narrower. Crucially, stress fiber bundles were significantly thicker in TRIM9-/- cells.
• Focal Adhesions (FAs): Loss of TRIM9 led to a significant increase in the number of focal adhesions, which were longer and narrower.
• VASP Dynamics:
  • In TRIM9+/+ cells, VASP was enriched at the tips of filopodia and lamellipodia.
  • In TRIM9-/- cells, VASP accumulated at focal adhesions and showed accelerated turnover dynamics (faster FRAP recovery).
  • Mechanism: TRIM9 interacts with VASP and promotes its multi-mono-ubiquitylation. This ubiquitination is required for the subsequent phosphorylation of VASP at Ser157. In the absence of TRIM9, VASP phosphorylation decreases, leading to altered localization and increased association with the cytoskeleton (triton-insoluble fraction).

C. Functional Consequences: Migration, Contractility, and Secretion

• Contractility: TRIM9-/- cells exhibited increased contractility, evidenced by greater contraction of collagen gels.
• Migration: TRIM9-/- cells showed increased instantaneous velocity but decreased directional persistence, consistent with a mesenchymal migration mode.
• Invasion: TRIM9-/- cells had enhanced invasive capacity through basement membranes (Transwell assays) and increased secretion of MMP-2 and Netrin-1.
• Proliferation: Contrary to the increased motility, TRIM9-/- cells had reduced proliferation rates (~26% slower) compared to TRIM9+/+ cells.

D. In Vivo Validation

• Tumor Growth: In the PBT mouse model, loss of Trim9 resulted in slower primary tumor growth and smaller tumor depth, consistent with the in vitro proliferation data.
• Metastasis: The effect on metastasis was complex:
  • TRIM9-/- mice showed reduced metastasis to the liver and brain.
  • However, they showed increased local metastasis (ear) and increased lung metastasis.
  • TRIM9+/+ tumors showed an inverse correlation between primary tumor size and metastatic burden (smaller primary tumors had more metastasis), a relationship lost in Trim9 KO mice.
• Clinical Correlation: High TRIM9 mRNA expression in human patient data (TCGA) correlated with poor overall survival and reduced response to immune checkpoint inhibitors (anti-PD-1 and anti-CTLA-4).

5. Significance

• Therapeutic Implications: The findings suggest that TRIM9 is a driver of aggressive melanoma phenotypes. High TRIM9 expression promotes a proliferative, bleb-based state that correlates with poor patient outcomes and immunotherapy resistance.
• Mechanistic Insight: The study defines a specific signaling axis (TRIM9 $\rightarrow$ VASP ubiquitination $\rightarrow$ VASP phosphorylation $\rightarrow$ Cytoskeletal remodeling) that controls the switch between amoeboid (bleb-based) and mesenchymal migration modes.
• Paradigm Shift: It challenges the view of TRIM9 solely as a tumor suppressor (as seen in pancreatic cancer) or a simple promoter of motility, demonstrating its context-dependent role in melanoma where it promotes proliferation and specific metastatic behaviors while suppressing others.
• Future Directions: The work opens avenues for targeting the TRIM9-VASP axis to force melanoma cells into a less aggressive, more adhesive state, potentially sensitizing them to immune therapies.